RESUMEN
A new tetramic acid glycoside, aurantoside L (1), was isolated from the sponge Siliquariaspongia japonica collected at Tsushima Is., Nagasaki Prefecture, Japan. The structure of aurantoside L (1) composed of a tetramic acid bearing a chlorinated polyene system and a trisaccharide part was elucidated using spectral analysis. Aurantoside L (1) showed anti-parasitic activity against L. amazonensis with an IC50 value of 0.74 µM.
Asunto(s)
Glicósidos , Leishmania , Poríferos , Poríferos/química , Animales , Glicósidos/farmacología , Glicósidos/química , Glicósidos/aislamiento & purificación , Leishmania/efectos de los fármacos , Antiprotozoarios/farmacología , Antiprotozoarios/química , Antiprotozoarios/aislamiento & purificación , Pirrolidinonas/farmacología , Pirrolidinonas/química , Pirrolidinonas/aislamiento & purificación , Japón , Concentración 50 InhibidoraRESUMEN
Two previously unreported onnamide analogs, 2Z- and 6Z-onnamides A (1 and 2), were isolated from the marine sponge Theonella conica collected at Amami-Oshima Is., Kagoshima Prefecture, Japan. Structures of compounds 1 and 2 were elucidated by spectral analysis. Structure-activity relationships (SARs) for effects on histone modifications and cytotoxicity against HeLa and P388 cells were characterized. The geometry in the polyene systems of onnamides affected the histone modification levels and cytotoxicity.
Asunto(s)
Poríferos , Theonella , Animales , Humanos , Theonella/química , Poríferos/química , Piranos , Células HeLa , Polienos/farmacología , Estructura MolecularRESUMEN
The 2018 marine pharmacology literature review represents a continuation of the previous 11 reviews of a series initiated in 1998. Preclinical marine pharmacology research during 2018 was performed by investigators in 44 countries and contributed novel pharmacology for 195 marine compounds. The peer-reviewed marine natural products pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 53 compounds, 73 compounds which presented antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 69 compounds were reported to show miscellaneous mechanisms of action which may contribute upon further investigation to several pharmacological classes. Thus, in 2018, the preclinical marine natural product pharmacology pipeline continued to report novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, which currently contributes to therapeutic strategies for several disease categories.
Asunto(s)
Antiprotozoarios , Productos Biológicos , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antifúngicos , Antiprotozoarios/farmacología , Antiprotozoarios/uso terapéutico , Antituberculosos/farmacología , Antituberculosos/uso terapéutico , Antivirales/farmacología , Antivirales/uso terapéutico , Productos Biológicos/farmacología , Productos Biológicos/uso terapéutico , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Biología Marina , Sistema NerviosoRESUMEN
Plants in the genus Curcuma have been widely used as traditional medicines in Asian countries. These plants contain bioactive compounds with neuroprotective properties or activities that increase neural stem cells (NSCs) and neurons. However, bioactive components in Curcuma that promote the differentiation of NSCs into astrocytes have not yet been reported. Here, the effects of Curcuma extracts on the in vitro differentiation of embryonic stem-cell-derived NSCs were evaluated. The extract of the wild turmeric, Curcuma aromatica, strongly promoted the differentiation of NSCs into astrocytes. Bioassay-guided isolation yielded coronarins C (1) and D (2), as well as (E)-labda-8(17),12-diene-15,16-dial (3) as the bioactive compounds. Coronarin D (2) markedly promoted the differentiation of NSCs into astrocytes up to approximately 4 times (3.64 ± 0.48) and increased the expression level of GFAP at the mRNA and protein level, while compounds 1 and 3 exhibited only weak effects, suggesting that the 15-hydroxy-Δ12-γ-lactone moiety is important for bioactivity. Moreover, compound 2 increased the number of pSTAT3-positive cells, suggesting that compound 2 promoted astrocytic differentiation through JAK/STAT signaling pathway.
Asunto(s)
Astrocitos , Células-Madre Neurales , Astrocitos/metabolismo , Diferenciación Celular , Células Cultivadas , Curcuma , Diterpenos , Células-Madre Neurales/fisiologíaRESUMEN
The review of the 2016-2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016-2017 assessed 313 marine compounds with novel pharmacology reported by a growing number of investigators from 54 countries. The peer-reviewed literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 123 marine natural products, 111 marine compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 79 marine compounds displayed miscellaneous mechanisms of action which upon further investigation may contribute to several pharmacological classes. Therefore, in 2016-2017, the preclinical marine natural product pharmacology pipeline generated both novel pharmacology as well as potentially new lead compounds for the growing clinical marine pharmaceutical pipeline, and thus sustained with its contributions the global research for novel and effective therapeutic strategies for multiple disease categories.
Asunto(s)
Organismos Acuáticos/química , Productos Biológicos/química , Productos Biológicos/farmacología , Sistema Inmunológico/efectos de los fármacos , Sistema Nervioso/efectos de los fármacos , Animales , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Antibacterianos/farmacología , Antiinflamatorios/química , Antiinflamatorios/aislamiento & purificación , Antiinflamatorios/farmacología , Antifúngicos/química , Antifúngicos/aislamiento & purificación , Antifúngicos/farmacología , Antiprotozoarios/química , Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/farmacología , Antituberculosos/química , Antituberculosos/aislamiento & purificación , Antituberculosos/farmacología , Antivirales/química , Antivirales/aislamiento & purificación , Antivirales/farmacología , Organismos Acuáticos/aislamiento & purificación , Productos Biológicos/aislamiento & purificación , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/aislamiento & purificación , Hipoglucemiantes/farmacología , Sistema Inmunológico/fisiología , Fenómenos Farmacológicos y ToxicológicosRESUMEN
The systematic review of the marine pharmacology literature from 2014 to 2015 was completed in a manner consistent with the 1998-2013 reviews of this series. Research in marine pharmacology during 2014-2015, which was reported by investigators in 43 countries, described novel findings on the preclinical pharmacology of 301 marine compounds. These observations included antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic pharmacological activities for 133 marine natural products, 85 marine compounds with antidiabetic, and anti-inflammatory activities, as well as those that affected the immune and nervous system, and 83 marine compounds that displayed miscellaneous mechanisms of action, and may probably contribute to novel pharmacological classes upon further research. Thus, in 2014-2015, the preclinical marine natural product pharmacology pipeline provided novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, and thus continued to contribute to ongoing global research for alternative therapeutic approaches to many disease categories.
Asunto(s)
Productos Biológicos/química , Productos Biológicos/farmacología , Sistema Inmunológico/efectos de los fármacos , Sistema Nervioso/efectos de los fármacos , Océanos y Mares , Animales , Antihelmínticos/farmacología , Antiinflamatorios/farmacología , Anticoagulantes/farmacología , Antifúngicos/farmacología , Antiprotozoarios/farmacología , Antituberculosos/farmacología , Antivirales/farmacología , Humanos , HipoglucemiantesRESUMEN
Sameuramide A (1), a new cyclic depsipeptide encompassing one each of alanine, N-methyl alanine, N-methyl dehydroalanine, N,O-dimethyl threonine, phenyllactic acid, three ß-hydroxy leucines, and two propionates, was isolated from a didemnid ascidian collected at the northern part of Japan. The planar structure was established based on the interpretation of MS and NMR data. The absolute configuration of the subunits was determined by the advanced Marfey's method and the chiral LC-MS analysis. Compound 1 exhibited the activity of maintaining colony formation of murine embryonic stem (mES) cells without leukemia inhibitory factor (LIF). Down regulation of the gene expression of Krüppel-like transcription factor 4 (Klf4) indicated that 1 itself was not able to maintain the undifferentiated state of the mES cells. However, the expression levels of the marker genes (Nestin, T, Sox17) for three germ layers were upregulated in embryoid bodies (EBs) after treatment of 1 together with LIF, suggesting that 1 plays a supportive role for LIF in maintaining the multipotency of mES cells.
Asunto(s)
Depsipéptidos/química , Urocordados/química , Animales , Diferenciación Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Depsipéptidos/aislamiento & purificación , Depsipéptidos/farmacología , Regulación hacia Abajo/efectos de los fármacos , Cuerpos Embrioides/citología , Cuerpos Embrioides/efectos de los fármacos , Cuerpos Embrioides/metabolismo , Células Madre Embrionarias , Proteínas HMGB/metabolismo , Factor 4 Similar a Kruppel , Factores de Transcripción de Tipo Kruppel/metabolismo , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Ratones , Conformación Molecular , Factores de Transcripción SOXF/metabolismo , Regulación hacia Arriba/efectos de los fármacos , Urocordados/metabolismoRESUMEN
Kakeromamide A (1), a new cyclic pentapeptide encompassing a thiazole ring moiety and a ß-amino acid, was isolated from the marine cyanobacterium Moorea bouillonii. Its structure was elucidated by the spectral analysis and the modified Marfey's method. Compound 1 induced differentiation of neural stem cells into astrocytes at the concentration of 10⯵M.
Asunto(s)
Antineoplásicos/farmacología , Astrocitos/efectos de los fármacos , Cianobacterias/química , Oligopéptidos/farmacología , Animales , Antineoplásicos/química , Antineoplásicos/aislamiento & purificación , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Ratones , Conformación Molecular , Oligopéptidos/química , Oligopéptidos/aislamiento & purificación , Relación Estructura-ActividadRESUMEN
The original article can be found online at https://doi.org/10.1038/ja.2017.145 .
RESUMEN
[This corrects the article DOI: 10.1007/s10164-017-0507-y.].
RESUMEN
Two new analogs of halistanol sulfate (1) were isolated from a marine sponge Halichondria sp. collected at Hachijo-jima Island. Structures of these new halistanol sulfates I (2) and J (3) were elucidated by spectral analyses. Compounds 1-3 showed inhibitory activity against SIRT 1-3 with IC50 ranges of 45.9-67.9, 18.9-21.1 and 21.8-37.5 µM, respectively. X-ray crystallography of the halistanol sulfate (1) and SIRT3 complex clearly indicates that 1 binds to the exosite of SIRT3 that we have discovered in this study.
Asunto(s)
Poríferos/química , Sirtuinas/antagonistas & inhibidores , Esteroles/aislamiento & purificación , Esteroles/farmacología , Animales , Antineoplásicos/aislamiento & purificación , Antineoplásicos/farmacología , Cristalografía por Rayos X , Ensayos de Selección de Medicamentos Antitumorales , Células HeLa , Humanos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Estructura Molecular , Sirtuina 1/antagonistas & inhibidores , Sirtuina 2/antagonistas & inhibidores , Sirtuina 3/antagonistas & inhibidores , Espectrometría de Masa por Ionización de Electrospray , Espectrofotometría UltravioletaRESUMEN
Males of the hermit crab Pagurus filholi perform assessment behavior toward females, as a preliminary step of precopulatory guarding, during the reproductive season. It is known that such behavior is elicited by female sex pheromones, but the compounds involved have never been characterized in this species. Several experiments were conducted to develop a reliable bioassay along with purification procedures to identify potential compounds with pheromonal activity in Pagurus filholi. We developed a bioassay protocol to assess pheromonal activity by using an empty shell with cotton containing either artificial seawater (control) or test water. We measured and compared the time duration of male assessment behavior toward each shell if the test water contained female sex pheromones. Ultra-filtering of seawater samples potentially containing pheromones showed that the compound was <1 kDa in molecular weight. Males showed precopulatory assessment behavior toward "female conditioned" water samples treated with open column purification and eluted with MeOH, suggesting that compounds triggering male behavior were low polar molecules. Molecules with pheromonal activity were not volatile after freeze drying, effective even after heating to 90 °C, and remained active in seawater at 12 °C even after 6 days from sample collection, which suggests a rather stable characteristic of the female sex pheromones of this species.
RESUMEN
The peer-reviewed marine pharmacology literature from 2012 to 2013 was systematically reviewed, consistent with the 1998-2011 reviews of this series. Marine pharmacology research from 2012 to 2013, conducted by scientists from 42 countries in addition to the United States, reported findings on the preclinical pharmacology of 257 marine compounds. The preclinical pharmacology of compounds isolated from marine organisms revealed antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral and anthelmitic pharmacological activities for 113 marine natural products. In addition, 75 marine compounds were reported to have antidiabetic and anti-inflammatory activities and affect the immune and nervous system. Finally, 69 marine compounds were shown to display miscellaneous mechanisms of action which could contribute to novel pharmacological classes. Thus, in 2012-2013, the preclinical marine natural product pharmacology pipeline provided novel pharmacology and lead compounds to the clinical marine pharmaceutical pipeline, and contributed significantly to potentially novel therapeutic approaches to several global disease categories.
Asunto(s)
Antifúngicos/farmacología , Antiprotozoarios/farmacología , Antituberculosos/farmacología , Antivirales/farmacología , Productos Biológicos/farmacología , Sueros Inmunes/efectos de los fármacos , Sistema Nervioso/efectos de los fármacos , Antiinflamatorios/farmacología , Anticoagulantes/farmacología , Organismos Acuáticos/efectos de los fármacos , Productos Biológicos/uso terapéutico , Humanos , Hipoglucemiantes/uso terapéutico , Biología MarinaRESUMEN
This review covers 214 marine natural compounds and 23 of their synthetic analogs, which were discovered and/or synthesized from mid-2009 to August 2014. The antifouling (AF) compounds reported have medium to high bioactivity (with a threshold of EC(50) < 15.0 mg ml(-1)). Among these compounds, 82 natural compounds were identified as new structures. All the compounds are marine-derived, demonstrating that marine organisms are prolific and promising sources of natural products that may be developed as environmentally friendly antifoulants. However, this mini-review excludes more than 200 compounds that were also reported as AF compounds but with rather weak bioactivity during the same period. Also excluded are terrestrial-derived AF compounds reported during the last five years. A brief discussion on current challenges in AF compound research is also provided to reflect the authors' own views in terms of future research directions.
Asunto(s)
Organismos Acuáticos/química , Incrustaciones Biológicas/prevención & control , Productos Biológicos/química , Alcaloides/química , Animales , Antozoos/química , Bacterias/química , Ácidos Grasos/química , Hongos/química , Estructura Molecular , Policétidos/química , Rhodophyta/química , Esteroides/química , Terpenos/química , Thoracica/químicaRESUMEN
Cinanthrenol A (1), a new steroid composed of a phenanthrene and a spiro[2,4]heptane system, was isolated from the marine sponge Cinachyrella sp. It is the first phenathrene-containing steroid with estrogen activity.
Asunto(s)
Estrógenos/aislamiento & purificación , Estrógenos/farmacología , Fenantrenos/química , Poríferos/química , Esteroides/aislamiento & purificación , Esteroides/farmacología , Animales , Estrógenos/química , Humanos , Biología Marina , Estructura Molecular , Esteroides/químicaRESUMEN
The peer-reviewed marine pharmacology literature from 2009 to 2011 is presented in this review, following the format used in the 1998-2008 reviews of this series. The pharmacology of structurally-characterized compounds isolated from marine animals, algae, fungi and bacteria is discussed in a comprehensive manner. Antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacological activities were reported for 102 marine natural products. Additionally, 60 marine compounds were observed to affect the immune and nervous system as well as possess antidiabetic and anti-inflammatory effects. Finally, 68 marine metabolites were shown to interact with a variety of receptors and molecular targets, and thus will probably contribute to multiple pharmacological classes upon further mechanism of action studies. Marine pharmacology during 2009-2011 remained a global enterprise, with researchers from 35 countries, and the United States, contributing to the preclinical pharmacology of 262 marine compounds which are part of the preclinical pharmaceutical pipeline. Continued pharmacological research with marine natural products will contribute to enhance the marine pharmaceutical clinical pipeline, which in 2013 consisted of 17 marine natural products, analogs or derivatives targeting a limited number of disease categories.
Asunto(s)
Organismos Acuáticos/química , Factores Biológicos/química , Factores Biológicos/farmacología , Sistema Inmunológico/efectos de los fármacos , Sistema Nervioso/efectos de los fármacos , Animales , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Antibacterianos/farmacología , Antiinflamatorios/química , Antiinflamatorios/aislamiento & purificación , Antiinflamatorios/farmacología , Antifúngicos/química , Antifúngicos/aislamiento & purificación , Antifúngicos/farmacología , Antiprotozoarios/química , Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/farmacología , Antituberculosos/química , Antituberculosos/aislamiento & purificación , Antituberculosos/farmacología , Antivirales/química , Antivirales/aislamiento & purificación , Antivirales/farmacología , Factores Biológicos/aislamiento & purificación , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/aislamiento & purificación , Hipoglucemiantes/farmacologíaRESUMEN
Using theonellasterol as a novel FXR antagonist hit, we prepared a series of semi-synthetic derivatives in order to gain insight into the structural requirements for exhibiting antagonistic activity. These derivatives are characterized by modification at the exocyclic carbon-carbon double bond at C-4 and at the hydroxyl group at C-3 and were prepared from theonellasterol using simple reactions. Pharmacological investigation showed that the introduction of a hydroxyl group at C-4 as well as the oxidation at C-3 with or without concomitant modification at the exomethylene functionality preserve the ability of theonellasterol to inhibit FXR transactivation caused by CDCA. Docking analysis showed that the placement of these molecules in the FXR-LBD is well stabilized when on ring A functional groups, able to form hydrogen bonds and π interactions, are present.
Asunto(s)
Receptores Citoplasmáticos y Nucleares/antagonistas & inhibidores , Esteroles/farmacología , Theonella/química , Animales , Células Hep G2 , Humanos , Simulación del Acoplamiento Molecular , Esteroles/síntesis química , Esteroles/química , Relación Estructura-ActividadRESUMEN
A new xenicane diterpenoid, cristaxenicin A (1), has been isolated from the deep sea gorgonian Acanthoprimnoa cristata. The structure of 1 was elucidated on the basis of spectral analysis including NMR and MS. The absolute configuration of 1 was determined on the basis of quantum chemical calculation of CD spectra. Cristaxenicin A (1) showed antiprotozoal activities against Leishmania amazonensis and Trypanosoma congolense with IC(50) values of 0.088 and 0.25 µM, respectively.
Asunto(s)
Antozoos/química , Antiprotozoarios/química , Antiprotozoarios/farmacología , Diterpenos/química , Leishmania/química , Leishmania/efectos de los fármacos , Animales , Diterpenos/farmacología , Concentración 50 Inhibidora , Espectroscopía de Resonancia Magnética , Estructura MolecularRESUMEN
The peer-reviewed marine pharmacology literature in 2007-8 is covered in this review, which follows a similar format to the previous 1998-2006 reviews of this series. The preclinical pharmacology of structurally characterized marine compounds isolated from marine animals, algae, fungi and bacteria is discussed in a comprehensive manner. Antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis and antiviral activities were reported for 74 marine natural products. Additionally, 59 marine compounds were reported to affect the cardiovascular, immune and nervous systems as well as to possess anti-inflammatory effects. Finally, 65 marine metabolites were shown to bind to a variety of receptors and miscellaneous molecular targets, and thus upon further completion of mechanism of action studies, will contribute to several pharmacological classes. Marine pharmacology research during 2007-8 remained a global enterprise, with researchers from 26 countries, and the United States, contributing to the preclinical pharmacology of 197 marine compounds which are part of the preclinical marine pharmaceuticals pipeline. Sustained preclinical research with marine natural products demonstrating novel pharmacological activities, will probably result in the expansion of the current marine pharmaceutical clinical pipeline, which currently consists of 13 marine natural products, analogs or derivatives targeting a limited number of disease categories.